Full Year 2025 Guidance
BeiGene's financial guidance is summarized below:
| FY 20251 | ||||
| Total Revenue | $4.9 billion to $5.3 billion | |||
| GAAP Operating Expenses (R&D and SG&A) | $4.1 billion to $4.4 billion | |||
| Additional: | GAAP Gross Margin Percentage in mid-80% range | |||
| Positive Full Year GAAP Operating Income | ||||
| Generation of Positive Cash Flow from Operations | ||||
BeiGene's total revenue guidance for full year 2025 of $4.9 billion to $5.3 billion includes expectations for strong revenue growth driven by BRUKINSA's U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the mid-80% range due to mix and production efficiencies as compared to 2024.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。